Mesalamine in the Initial Therapy of Ulcerative Colitis.
Inflammatory bowel disease is a chronic disorder of intestinal inflammation and includes Crohn's disease and ulcerative colitis. The goal of therapy is to induce and maintain remission, which is achieved with conventional therapies. Mesalamine is considered a first-line therapy for ulcerative colitis. Clinical trials have confirmed its efficacy and safety in patients with mild to moderate ulcerative colitis. Doses of more than 2.4 g/d achieve significantly higher rates of clinical and endoscopic remission, with a decreased risk of relapse. Serious adverse effects are rare, but nonadherence is common. Mesalamine is considered safe in pregnancy, excluding formulations with dibutyl phthalate.
['Chibbar|Richa|R|', 'Moss|Alan C|AC|']
D000894:Anti-Inflammatory Agents, Non-Steroidal D003093:Colitis, Ulcerative D003993:Dibutyl Phthalate D004339:Drug Compounding D016099:Endoscopy, Gastrointestinal D005260:Female D006801:Humans D060046:Maintenance Chemotherapy D008297:Male D019804:Mesalamine D011247:Pregnancy D011248:Pregnancy Complications D011788:Quality of Life D012074:Remission Induction D012449:Safety D055502:Secondary Prevention
Therapy Ulcerative colitis Inflammatory bowel disease Chronic disorder Dibutyl phthalate Crohn’s disease Endoscopic healing